Key Points
- Director Tim Kutzkey acquired 315,457 shares at an average price of $12.65 (≈$3.99M), boosting his ownership to 962,718 shares—a 48.74% increase disclosed in an SEC filing.
- Surrozen reported steep losses last quarter with EPS of ($3.61) versus consensus ($1.17) and just $0.98M in revenue, leaving the company with highly negative margins and analysts projecting -8.49 EPS for the year.
- The stock trades at $15.54 with a 12‑month range of $5.90–$18.17 and a market cap of $133.18M, while analyst coverage is mixed but carries a consensus "Moderate Buy" and a $38.50 price target.
Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) Director Tim Kutzkey acquired 315,457 shares of the firm's stock in a transaction dated Thursday, November 13th. The shares were bought at an average cost of $12.65 per share, with a total value of $3,990,531.05. Following the completion of the acquisition, the director directly owned 962,718 shares of the company's stock, valued at $12,178,382.70. The trade was a 48.74% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.
Surrozen Trading Down 3.6%
Shares of SRZN stock opened at $15.54 on Wednesday. Surrozen, Inc. has a 12-month low of $5.90 and a 12-month high of $18.17. The stock has a market capitalization of $133.18 million, a P/E ratio of -0.70 and a beta of 0.62. The firm's 50 day moving average is $13.51 and its 200 day moving average is $11.11.
Surrozen (NASDAQ:SRZN - Get Free Report) last announced its earnings results on Friday, November 7th. The company reported ($3.61) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by ($2.44). The company had revenue of $0.98 million for the quarter. Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. As a group, equities analysts predict that Surrozen, Inc. will post -8.49 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of analysts recently commented on the company. Wall Street Zen raised Surrozen to a "sell" rating in a report on Friday, November 28th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Surrozen in a research report on Wednesday, October 8th. Finally, Lifesci Capital upgraded shares of Surrozen to a "strong-buy" rating in a research note on Thursday, November 13th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $38.50.
Check Out Our Latest Report on Surrozen
Institutional Trading of Surrozen
Several hedge funds have recently bought and sold shares of the stock. Stempoint Capital LP raised its stake in shares of Surrozen by 185.1% in the second quarter. Stempoint Capital LP now owns 686,539 shares of the company's stock worth $6,138,000 after buying an additional 445,713 shares during the period. RA Capital Management L.P. increased its holdings in Surrozen by 140.3% in the 1st quarter. RA Capital Management L.P. now owns 679,130 shares of the company's stock worth $7,919,000 after acquiring an additional 396,550 shares in the last quarter. 5AM Venture Management LLC bought a new stake in Surrozen during the 1st quarter worth approximately $3,615,000. Stonepine Capital Management LLC lifted its holdings in Surrozen by 7.1% during the second quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company's stock valued at $2,736,000 after purchasing an additional 20,247 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Surrozen by 21.7% during the third quarter. Vanguard Group Inc. now owns 266,418 shares of the company's stock valued at $3,433,000 after purchasing an additional 47,468 shares in the last quarter. Institutional investors own 66.57% of the company's stock.
Surrozen Company Profile
(
Get Free Report)
Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
